Loading…
CMND
Clearmind Medicine Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 185053600
$1.76-2.76%Price as of Aug 29, 18:49 UTC · updated once a day, after the close
Key metrics
- Market cap
- $2.61M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.2x
- Dividend yield
- —
- Payout
- —
- EPS
- -$175.92
- ROE
- -114.61%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -1.18
- 52-week high
- $524.00
- 52-week low
- $1.43
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $18.10 | $552.00 | $1,124.00 | $37,920.00 | |
| P/B | 1.7x | 0.2x | 1.9x | 1.7x | — |
| EPS | -$303.50 | -$678.00 | -$5,679.08 | -$63,440.20 | |
| ROE | -323.41% | -323.41% | -169.09% | -876.57% | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| IVFINVO Fertility, Inc. | $1.00 | 0.0x | 0.1x | — | -55.28% | $2.51M |
| PPBTPurple Biotech Ltd | $1.68 | — | 0.2x | — | -111.13% | $2.73M |
| NUWENuwellis, Inc. | $0.89 | 0.0x | — | — | — | $2.82M |
| ONCOOnconetix, Inc. | $0.61 |
About the company
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
- Vancouver, Canada
Company description provided by Yahoo Finance.